| Mepha Pharma AG - Atazanavir-Mepha 150mg, Kapseln | | 66339 | | 01 | | Atazanavir-Mepha 150mg | | Kapseln | | J05AE08 | | Atazanavir | | 19.09.2017 | | |
| | Composition | | atazanavirum 150 mg ut atazanaviri sulfas, lactosum monohydricum 67.203 mg, crospovidonum, magnesii stearas, Kapselhülle: gelatina, E 171, E 132, Drucktinte: lacca, E 172 (nigrum), propylenglycolum, ammoniae solutio 28 per centum, pro capsula. | | Packungsbestandteile | | Capsules | | | | Principe actif | Concentr. |
|---|
| Atazanavir | 150 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| (Nigrum) | | | | Ammoniae Solutio | 28 | | | Crospovidonum | | | | E 132 | | color. | | E 171 | | color. | | E 172 | | color. | | Gelatina | | Kapselhülle | | Lacca | | Drucktinte | | Lactose Monohydrate | 67.203 mg | | | Magnesii Stearas | | | | Per Centum | | | | Pro Capsula | | | | Propylenglycol | | |
|
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 001 | 60 | DDP | DDP | A | | Oui |
|
|
